Trials / Recruiting
RecruitingNCT06833229
Prospective Cohort Study Evaluating 18FDG PET-CT for the Early Prediction of the Efficacy of Immunotherapy Associated or Not With Chemotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Broncho-Pulmonary Carcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Centre Antoine Lacassagne · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis of this prospective observational pilot study of diagnostic diagnostic performance is that, for patients with NSCLC treated with immunotherapy associated or not with chemotherapy, certain metabolic biomarkers on 18FDG PET scans allow early identification of treatment response (or lack of response to treatment) and optimize prediction of tumor response compared with current standards.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | FDG-PET | PET scan are performed within 28 days before the start of immunotherapy, then at week 6 and week 12 of follow-up. Various metabolic parameters extracted from the standard PET image (ΔSUVmax, ΔTLG, appearance of new visceral lesion(s)), parametric (metabolic glucose rate (Ki), volume of distribution (VD)) and tumor response based on PERCIST criteria (adapted to immunotherapy) are assessed. |
Timeline
- Start date
- 2022-01-27
- Primary completion
- 2028-05-27
- Completion
- 2031-01-27
- First posted
- 2025-02-18
- Last updated
- 2025-04-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06833229. Inclusion in this directory is not an endorsement.